Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapyChrista E. Nath, John Earl, Peter J. Shaw et al.|British Journal of Clinical Pharmacology|2010Cited by 80
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E. Nath, Peter J. Shaw, Campbell Tiley et al.|British Journal of Clinical Pharmacology|2016Cited by 59
A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 StudyStephen P. Mulligan, Bryone J. Kuss, Campbell Tiley et al.|Blood|2012Cited by 14
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct StudyDavid T Yeung, On Behalf of the ALLG, Andrew Grigg et al.|Blood|2019Cited by 3
P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACYDavid T Yeung, Timothy P. Hughes, Andrew Grigg et al.|HemaSphere|2022Cited by 1